Nigerian Doctor In U.S Leads Major Study On Antiviral Covid-19 Drug That Has Shown Promise [Video]

May 1, 2020
126 Views

U.S based Nigerian doctor, is leading a major study on an antiviral drug named ‘’ that appears to be effective in treating .

Dr Taiwo was interviewed by CNN and he explained the promising result of the drug in treating COVID-19 patients.

According to him, the preliminary results of Remdesivir shows that the drug can help hospitalised COVID-19 patients recover faster, but it does not significantly reduce death.

The US Food and Drug Administration has not yet approved any drugs for the treatment of the coronavirus. But it plans to announce an emergency-use authorization for remdesivir, according to The New York Times.

Watch the interview below:

[embedded content]
Subscribe to Kanyi TV
[embedded content]

KanyiDaily recalls that President Donald Trump had also approved the use of anti-malarial drug, Chloroquine, for the treatment of the coronavirus disease in the United States.

You may be interested

UCL: Atletico Madrid Will Come Out Stronger Against Borussia Dortmund –Simeone
Sports
1 views
Sports
1 views

UCL: Atletico Madrid Will Come Out Stronger Against Borussia Dortmund –Simeone

Webby - April 16, 2024

Atletico Madrid coach Diego Simeone has disclosed that the team has a stronger game plan to overcome Borussia Dortmund in…

7 Players Who Merit Super Eagles Call-up For Next 2026 W/Cup Qualifiers
Sports
1 views
Sports
1 views

7 Players Who Merit Super Eagles Call-up For Next 2026 W/Cup Qualifiers

Webby - April 16, 2024

The Super Eagles will take on South Africa and Benin Republic in the 2026 FIFA World Cup qualifiers in June.After…

The Hidden Truth That Led To Killing Of 17 Soldiers In Okuama Delta State
News
4 views
News
4 views

The Hidden Truth That Led To Killing Of 17 Soldiers In Okuama Delta State

Webby - April 16, 2024

A feud between an illegal oil bunker, Endurance Okodeh alias Amangbein and a sophisticated cartel of powerful illegal oil bunkers…

Leave a Comment

Your email address will not be published.